Abstract Details

Title Impact of Anticonvulsant Treatment on Cognitive Function and Epileptic Activity in Alzheimer's Disease Patients

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P1 - Poster Session 1 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-018

Objective

Investigate the correlation between demographic and clinical factors, including anticonvulsant treatment, cognitive performance, and seizure frequency in epilepsy patients diagnosed with Alzheimer's Disease (AD).

Background

AD is associated with cognitive decline and is frequently complicated by epilepsy. This study explores the interplay between demographic factors, epilepsy characteristics, and cognitive outcomes in patients treated with anticonvulsants (phenobarbital and levetiracetam), aiming to better understand their relationships and impacts.

Design/Methods A cross sectional study was conducted with a cohort of 51 patients diagnosed with both AD and epilepsy. It was analyzed using Pearson correlation coefficients to assess relationships between age, sex, race, education level, Mini-Mental State Examination (MMSE) scores, MoCA scores (before and after treatment), anticonvulsant dosages, epilepsy frequency and type. Statistical significance was determined at the p<0.05 level.

Results Among the 51 patients the mean age was 82.29 years (SD=5.96) and 52.9% were female. Significant correlations were found. Age of AD diagnosis was strongly positively correlated with both current age (r=0.991, p<0.001) and age of epilepsy onset (r=0.728, p<0.001). A notable negative correlation was observed between sex and education level (r=0.325, p=0.020). MoCA Test scores six months after treatment were positively correlated with initial MoCA scores (r=0.629, p<0.001) with significant improvement from scores prior intervention. The frequency of epilepsy per month negatively correlated with post-treatment MoCA scores (r=-0.250, p=0.076) and was strongly negatively correlated with seizure frequency during treatment (r=-0.294, p=0.036). Additionally, higher anticonvulsant dosages were associated with poorer MMSE scores after six months of therapy (r=-0.917, p<0.001).

Conclusions

Higher doses of anticonvulsants were associated with worse cognitive outcomes, while effective treatment resulted in reduced seizure frequency and improved cognitive scores. This highlights the need for personalized treatment approaches that prioritize both seizure control and cognitive preservation in AD patients. Further research is needed to explore the long-term effects of anticonvulsant therapy on cognitive decline.

Authors/Disclosures
Linker E. Viñan Paucar, Sr. (American Chistian School) PRESENTER	Mr. Viñan Paucar has nothing to disclose.
Maria G. Chacon	Dr. Chacon has nothing to disclose.
Isabella S. Egüez (Universidad Católica Santiago de Guayaquil)	Mrs. Egüez has nothing to disclose.
Danny J. Japon (Universidad Catolica Santiago de Guayaquil)	Mr. Japon has nothing to disclose.
Carlos A. Rodríguez Alarcón, MD	Dr. Rodríguez Alarcón has nothing to disclose.
Andre Paszkiewicz Salcedo, Sr., Student	Mr. Paszkiewicz Salcedo has nothing to disclose.
Soledad M. Salazar, Student	Miss Salazar has nothing to disclose.
María G. Rimbaldo, Miss	Miss Rimbaldo has nothing to disclose.
Luis F. Leyton Aguilar, MD	Dr. Leyton Aguilar has nothing to disclose.
Estefania Jackeline Suquilanda Rovayo	Miss Suquilanda Rovayo has nothing to disclose.
Genesis Y. Loor, Jr., MD	Miss Loor has nothing to disclose.
Daniel E. Ocampo, Sr., MD	Dr. Ocampo has nothing to disclose.
Presley M. Gruezo, Jr.	Mr. Gruezo has nothing to disclose.
Luis Yepez	Luis Yepez has nothing to disclose.
Rocio A. Santibanez, MD, FAAN (Universidad Catolica de Santiago de Guayaquil)	Dr. Santibanez has nothing to disclose.

��ɫ��

��ɫ��